CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shilkaitis, A.
Right arrow Articles by Christov, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shilkaitis, A.
Right arrow Articles by Christov, K.
Cell Growth & Differentiation Vol. 11, 437-445, August 2000
© 2000 American Association for Cancer Research

Bcl-2 and Bax Are Differentially Expressed in Hyperplastic, Premalignant, and Malignant Lesions of Mammary Carcinogenesis1

Anne Shilkaitis, Jewell Graves, Rajeshwari R. Mehta, Lan Hu, Ming You, Ronald Lubet, Vernon Steele, Gary Kelloff and Konstantin Christov2

Department of Surgical Oncology, University of Illinois at Chicago, Chicago, Illinois 60612 [A. S., J. G., R. R. M., K. C.]; Department of Pathology, Medical College of Ohio, Toledo, Ohio 43699 [L. H., M. Y.]; and National Cancer Institute Division for Cancer Prevention, Bethesda, Maryland 20852 [R. L., V. S., G. K.]

Previously, we found that vorozole (Vz), a nonsteroidal aromatase inhibitor, suppresses the development and progression of mammary tumors in rats. Here we evaluated for the first time the expression of cell death-related proteins Bcl-2 and Bax in hyperplastic, premalignant (carcinoma in situ), or malignant (carcinoma) lesions of mammary carcinogenesis; we also assessed whether these proteins are involved in mediating Vz-induced cell death in tumors. We found that Bcl-2 and Bax were equally expressed in epithelial cells of terminal end buds, ducts, and alveoli. However, in myoepithelial cells, the level of Bax expression was much higher than the level of Bcl-2 expression. Bcl-2 and Bax levels in hyperplastic lesions were similar to those of normal mammary epithelial cells but lower in most carcinomas in situ and carcinomas. In animals with established mammary tumors, Vz induced apoptotic cell death, which was primarily associated with a decrease in Bcl-2 and, to a lesser extent, with a decrease in Bax. These data support the hypothesis that Bcl-2 loss is more potent than Bax gain in regulating apoptotic cell death in mammary tumors.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. F. Badawi, M. B. Eldeen, Y. Liu, E. A. Ross, and M. Z. Badr
Inhibition of Rat Mammary Gland Carcinogenesis by Simultaneous Targeting of Cyclooxygenase-2 and Peroxisome Proliferator-activated Receptor {gamma}
Cancer Res., February 1, 2004; 64(3): 1181 - 1189.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2000 by the American Association of Cancer Research.